 PRINCETON, NJ ACCESSWIRE August 19, 2021 Sonnet BioTherapeutics Holdings, Inc. NASDAQ:SONN Sonnet or the Company, a biopharmaceutical company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 35,294,117 shares of common stock or common stock equivalents which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock and investor warrants to purchase up to an aggregate of 35,294,117 shares of common stock. Each share of common stock or pre-funded warrant in lieu thereof is being sold together with one investor warrant to purchase one share of common stock at a combined offering price of 0.85, for total gross proceeds of approximately 30.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet. 